Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments

J Pediatr Hematol Oncol. 2023 Apr 1;45(3):152-154. doi: 10.1097/MPH.0000000000002643. Epub 2023 Feb 20.

Abstract

Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare disorder that causes significant neurodevelopmental sequelae in children. Approximately half of pediatric OMAS cases are paraneoplastic, typically associated with localized neuroblastic tumors. Since early persistence or relapse of OMAS symptoms is common even after tumor resection, OMAS relapses may not routinely prompt reevaluation for recurrent tumors. We report a 12-year-old girl with neuroblastic tumor recurrence associated with OMAS relapse a decade after initial treatment. Providers should be aware of tumor recurrence as a trigger for distant OMAS relapse, raising intriguing questions about the role of immune surveillance and control of neuroblastic tumors.

Publication types

  • Case Reports

MeSH terms

  • Ataxia / complications
  • Ataxia / therapy
  • Child
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Opsoclonus-Myoclonus Syndrome* / etiology
  • Opsoclonus-Myoclonus Syndrome* / therapy